أعرض في EDS

Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model

التفاصيل البيبلوغرافية
العنوان: Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model
المؤلفون: Chia-Yu Yu, Min-Hua Chen, Chih-Hsien Chang, Ya-Jen Chang, Liang-Cheng Chen, Tsui-Jung Chang, Gann Ting, Te-Wei Lee
المصدر: Nuclear Medicine and Biology. 37:95-104
بيانات النشر: Elsevier BV, 2010.
سنة النشر: 2010
مصطلحات موضوعية: Male, Cancer Research, Biodistribution, Pathology, medicine.medical_specialty, Maximum Tolerated Dose, Combination therapy, Colorectal cancer, medicine.medical_treatment, Mice, Drug Stability, Drug Therapy, Pharmacokinetics, In vivo, Cell Line, Tumor, medicine, Animals, Tissue Distribution, Radiology, Nuclear Medicine and imaging, Doxorubicin, Radioisotopes, Tomography, Emission-Computed, Single-Photon, Chemotherapy, Radiotherapy, business.industry, Cancer, X-Ray Microtomography, medicine.disease, Combined Modality Therapy, Survival Analysis, Tumor Burden, Disease Models, Animal, Rhenium, Treatment Outcome, Colonic Neoplasms, Injections, Intravenous, Cancer research, Autoradiography, Molecular Medicine, business, medicine.drug
الوصف: Nanocarriers can selectively target cancer sites and carry payloads, thereby improving diagnostic and therapeutic effectiveness and reducing toxicity. The objective of this study was to investigate the therapeutic efficacy of a new co-delivery radiochemotherapeutics of 188 Re- N , N -bis (2-mercaptoethyl)- N ′, N ′-diethylethylenediamine (BMEDA)-labeled pegylated liposomal doxorubicin (DXR) ( 188 Re-DXR-liposome) in a C26 murine colon carcinoma solid tumor model. To evaluate the targeting and localization of 188 Re-DXR-liposome in C26 murine tumor-bearing mice, biodistribution, microSPECT/CT imaging and pharmacokinetic studies were performed. The antitumor effect of 188 Re-DXR-liposome was assessed by tumor growth inhibition, survival ratio and histopathological hematoxylin–eosin staining. The tumor target and localization of the nanoliposome delivery radiochemotherapeutics of 188 Re-DXR-liposome were demonstrated in the biodistribution, pharmacokinetics and in vivo nuclear imaging studies. In the study on therapeutic efficacy, the tumor-bearing mice treated with bimodality radiochemotherapeutics of 188 Re-DXR-liposome showed better mean tumor growth inhibition rate (MGI) and longer median survival time (MGI=0.048; 74 days) than those treated with radiotherapeutics of 188 Re-liposome (MGI=0.134; 60 days) and chemotherapeutics of Lipo-Dox (MGI=0.413; 38 days). The synergistic tumor regression effect was observed with the combination index (CI) exceeding 1 (CI=1.145) for co-delivery radiochemotherapeutics of 188 Re-DXR-liposome. Two (25%) of the mice treated with radiochemotherapeutics were completely cured after 120 days. The therapeutic efficacy of radiotherapeutics of 188 Re-liposome and the synergistic effect of the combination radiochemotherapeutics of 188 Re-DXR-liposome have been demonstrated in a C26 murine solid tumor animal model, which pointed to the potential benefit and promise of the co-delivery of nanoliposome radiochemotherapeutics for adjuvant cancer treatment on oncology applications.
تدمد: 0969-8051
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46013eeb2816964c62d393ac5b09693b
https://doi.org/10.1016/j.nucmedbio.2009.08.006
حقوق: CLOSED
رقم الأكسشن: edsair.doi.dedup.....46013eeb2816964c62d393ac5b09693b
قاعدة البيانات: OpenAIRE
الوصف
تدمد:09698051